Targeting Postprandial Hyperglycemia with fixed dose combination of repaglinide and voglibose in Type 2 Diabetes Mellitus
- Author:
Arif A. Faruqui,
;
Kanchan Choudhary
;
ahul M. Kakalij
- Publication Type:Journal Article
- Keywords:
Diabetes mellitus;
Voglibose;
Repaglinide;
FBG;
PPBG;
HbA1c.
- From:
Pacific Journal of Medical Sciences
2018;18(2):55-61
- CountryPapua New Guinea
- Language:English
-
Abstract:
Present study evaluates efficacy and tolerability of fixed dose combination of Voglibose and Repaglinide in postprandial hyperglycemia (PPHG).A non-randomized, open labeled, non-comparative, multi-centric, study was conducted in 69 Type 2 diabetes mellitus (T2DM) patients, 53 (76.8%) men and 16 (23.2%) women. Each patient was administered a fixed dose combination of voglibose 0.3mg and repaglinide 1mg twice a day, just before each meal for 90 days. Fasting blood glucose (FBG) and postprandial blood glucose (PPBG) levels were measured at baseline (day zero), on day 30 and on day 90. Glycated Haemoglobin (HbA1c) was measured at baseline and on day 90. There was significant reduction in PPBG (31.2%), FBG (31.6%), and HbA1c (10.3%) on day 90 compared to baseline. Therefore fixed dose combination of voglibose 0.3mg and repaglinide 1mg has a considerable impact on PPBG control. This combination was found to be efficacious in controlling PPHG and no cases of hypoglycemia were reported.
